THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS Russian patent published in 2023 - IPC A61K38/17 A61K39/395 C07K16/24 A61P15/00 

FIELD: pharmaceutical industry.

SUBSTANCE: group of inventions relates specifically to the use of an IL-33 antagonist in the treatment of endometrial tissue disease, where this endometrial tissue disease is selected from endometriosis and adenomyosis. The use of a therapeutic agent containing an IL-33 antagonist as an active ingredient is provided for the relief of pain in an endometrial tissue disease, where this endometrial tissue disease is selected from endometriosis and uterine adenomyosis, in the treatment, prevention or relief of this disease. The use of a therapeutic agent containing an IL-33 antagonist as an active ingredient to inhibit adhesion of ectopic endometrial tissue and/or cysts to various organs in the treatment, prevention or alleviation of a disease endometrial tissue in a patient wherein this endometrial tissue disease is selected from endometriosis and uterine adenomyosis, wherein this IL-33 antagonist is selected from an anti-IL-33 antibody, an antibody directed against an IL-33 receptor, or a soluble IL-33 receptor. Use of an antibody selected from A10-1C04, A23-1A05, A25-2C02, A25-3H04, or A26-1F02 for the treatment, prevention, or amelioration of endometriosis or uterine adenomyosis.

EFFECT: therapeutic agent containing an IL-33 antagonist as an active ingredient is effective for relieving pain, for inhibiting adhesion of ectopic endometrial tissue and/or cysts to various organs in the treatment, prevention or alleviation of endometrial tissue disease in a patient where this endometrial disease tissues selected from endometriosis and adenomyosis of the uterus, and the use of an antibody selected from A10-1C04, A23-1A05, A25-2C02, A25-3H04 or A26-1F02 is effective for treating, preventing or relieving uterine endometriosis or adenomyosis.

8 cl, 6 dwg, 2 tbl, 8 ex